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Abstract
Background: Median survival of metastatic malignant melanoma is 6.0 to 7.5 months, with a 5-
year survival of ~6.0%. Although long-term complete remissions are rare, few reports describe
cases after chemotherapy. Fifty-three patients with metastatic melanoma were treated with
Cystemustine, a chloroethyl nitrosourea (CENU) (60 or 90 mg/m2).
Case presentation: We describe 5 cases, presenting with complete response with long-term
disease-free survival of long-term remission of 14, 12, 9, 7 and 6 years after Cystemustine therapy
alone.
Conclusion: Long-term survival has already been described in literature, but in all cases they have
been obtained after chemotherapy associated with or followed by surgery. But despite these
noteworthy and encouraging but also rare results, it appears essential to increase cystemustine
efficiency.
Background
Melanoma has become an important public health issue
because of its rising incidence in the Caucasian popula-
tion. Even though, most cases are cured by surgery alone
in the early stages of the disease, advanced melanoma has
a poor prognosis. Therapeutic strategies of metastatic
malignant melanoma are based on multiple treatment
including chemotherapy (dacarbazine, platinum analogs,
chloronitrosoureas (CENU), vinca alkaloïds or taxanes)
and immunotherapy (interferon α, interleukine 2), both
as single agents or in association.
Median survival of metastatic malignant melanoma is 6.0
to 7.5 months, with a 5-year survival of approximately 6%
[1]. Although long-term complete remissions are rare,
some authors have reported cases after chemotherapy
treatment [2-6].
Cystemustine {N'-(2-chloroethyl)-N- [2-(methyl sulpho-
nyl)ethyl]-N'-nitrosourea} is a CENU derived from 2-
chloro-ethylnitroso-carbamoylcysteamine (CCNC); it is
synthesised in INSERM U484, Clermont-Ferrand [7]. This
new compound has demonstrated an equivalent and
often better chemotherapeutic index for solid tumours
than other chloroethylating agents currently in use [8].
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We describe 5 cases treated with Cystemustine (60 or 90
mg/m2) for metastatic melanoma showing complete
responses with long-term survival (survival time 24
months or longer).
Case Presentation
A series of 53 patients has been treated with Cystemustine
administered as a 15 min iv infusion every 2 weeks. 30
patients were included in a phase II national and multi-
centric study, whereas other 23 patients received a
Cystemustine compassionate treatment.
In the phase II study, patients provided written informed
consent after they were informed about the objectives of
the study. The protocol designs and relative modifications
were fully approved by the ethic committee. The patients
received Cystemustine 60 or 90 mg/m2. The median
number of Cystemustine cycles was 3 (range, 2 to 7
cycles). 28 out of 30 patients were assessed for disease
response (2 patients were included without measurable
disease according to World Health Organisation (WHO)
criteria. The overall response rate was 17.9%, with 3 com-
plete responses and 2 partial responses. Two patients
showing complete response had been treated with
Cystemustine 90 mg/m2, the third patient received
Cystemustine 60 mg/m2.
Patients given "compassionate treatment" received 60
mg/m2 of Cystemustine. The median number of
Cystemustine cycles was 3 (range, 1 to 27 cycles). Among
these 23 patients, 15 were assessed for disease response
(i.e. patients with measurable disease according to WHO
criteria). Four complete and two partial responses were
observed. All patients were treated with Cystemustine 60
mg/m2.
Among these 53 patients, 5 complete responses with long-
term survival occurred. In 4 cases, complete responses
were obtained after Cystemustine treatment alone,
whereas, for the fifth patient, one of the metastatic lesions
was excised at the early beginning of the treatment. The
characteristics of these 5 patients are summarised in the
"patient characteristics" table 1.
Patient 1 was a 55 year woman presented with a level III
Clark right ankle malignant melanoma excised on April
1981. In 1988, she displayed an inoperable popliteal
mass associated with a large right inguinal adenopathy.
Between March and August 1988, she received 13 cycles of
Cystemustine 90 mg/m2. CR was documented by clinical
and echographic exams in August 1988. The main toxici-
ties of treatment were nausea, vomiting and thrombope-
nia. These last ones have led to dose reduction and
treatment delay. This patient died of stroke on November
2000 without any recurrence of the disease.
Patient 2 was a 33 year woman presented with a level IV
Clark left calf malignant melanoma excised on August
1985. Between 1986 and 1990, several relapse of
melanoma were diagnosed. The patient has been succes-
sively treated with vindesine/dacarbazine, vindesine/
dacarbazine, and dacarbazine/interferon α. Hormono-
Table 1: Patient characteristics.
Patient 1 2 3 4 5
Patient age/disease 
discovery (year)
55 33 63 44 43
Primary disease date April 1981 August 1985 January 1984 January 1997 August 1993
Primary disease location Right ankle Left calf Left ankle Left arm Left thorax
Clarck index III V IV III III
First recurrence date March 1988 June 1986 April 1987 January 1997 March 1998
Previous treatment for 
advanced 
disease (before 
cystemustine)
None Dacarbazine Vindesine 
(6 cycles)
Dacarbazine Vinblastine 
(6 cycles)
Dacarbazine Interferon α 2a 
(6 cycles)
Interferon α 2a 
Radiotherapy
None Dacarbazine 
(8 cycles)
Treatment start date March 1988 May 1990 August 1990 February 1997 Novembre 1998
Custemustine dose (mg/m2) 90 60 90 90 60
Metastatic sites Popliteal mass 
Lymph node
Lung Bone Lymph node Lymph node Sub-
cutaneous
Lung
Treatment concomitant to 
Cystemustine
Surgery (March 
1988)
None None None None
Recurrence of the disease None None None None None
Date of death November 2000 Alive March 2000 Alive Alive
Disease free survival (years) 12 14 10 7 6
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therapy with tamoxifene was then introduced with close
clinical follow-up. In 1990, she presented with right tibiae
metastasis and two pulmonary lesions. Treatment with
Cystemustine 60 mg/m2 was introduced for 18 cycles.
After 6 cycles, complete regression of pulmonary lesions
was observed, but bone lesions were always present in
spite of a significant improvement. Tumour assessment
after 17 cycles revealed CR to treatment. The main toxicity
was haematological, with neutropenia and thrombope-
nia, that necessitated course delay and dose reduction.
Patient 3 was a 63 year woman presenting with Clark level
IV malignant melanoma on left ankle, excised in January
1984. Three years later, tumour recurrence was diagnosed
on the left calf. An adjuvant treatment with interferon was
introduced (but interrupted after the first infusion
because of an allergic reaction), followed by 3 × 18 Gy
cycles of radiotherapy in June 1987. In August 1988, a
node was detected at the lower part of the left popliteal
pit, and was excised in December 1988. In September
1990, supra-clavicular and lombo-aortic nodes were
detected. The patient received 11 cycles of Cystemustine
90 mg/m2, and a CR was obtained after 8 cycles. Haema-
tological toxicities occurred with severe thrombopenia,
leading to course delays and platelet transfusion after the
8th infusion. Except for the haematological toxicity, treat-
ment was well tolerated. However, a systematic explora-
tion of respiratory function in January 2000 showed a
severe hypoxia and confirmed the diminution of carbon
monoxide capacity found 5 years earlier.
In July 1998, myelodisplasic syndrome was diagnosed.
She died in March 2000 during severe aplasia, neverthe-
less her meanoma was still in complete remission for 9
years and a month.
Patient 4 was a 44 year male presenting Clark level III
malignant melanoma located on left arm. Tumour exci-
sion was performed on January 1997 and completed with
a node dissection. One node of 11 removed was meta-
static. Imaging assessment found also a superficial 2 cm
left axillary node as well as 2 – 3 infracentimetric meta-
static subcutaneous nodes in the chest wall. The patient
received 6 cycles of Cystemustine 90 mg/m2. Target size
decreased after 2 cycles, and the patient was CR at the end
of treatment. No relevant toxicity was reported, except an
episode of febrile aplasia after the 6th cycle leading to red
blood cells and platelets transfusion.
Patient 5 was a 43 year male presenting with a Clark level
III cutaneous thoracic melanoma lesion excised on August
1993. Surgery was completed by a wide local excision
margin of 3 cm of the scar. Disease assessment imaging
revealed no metastasis. The patient was then followed
every 3 months.
Several pulmonary node metastasis were found in March
1998. The patient received 8 cycles of dacarbazine, and
because of new disease progression, he received six cycles
of Cystemustine 60 mg/m2 every 2 weeks. The patient was
considered in complete remission after 2 cycles of
Cystemustine. No significant toxicity was reported during
the treatment.
Among these five patients, three remain in long-term
remission for 14, 7 and 6 years after Cystemustine mono-
therapy. Of the other 2 patients, one (patient 1) died from
a stroke after a 12 years survival without disease recur-
rence. The second (patient 3) presented with a myelodys-
plastic syndrome treated with cytarabine. This patient
died in March 2000 from severe aplasia, and at this time
her melanoma was still in complete remission after 9
years.
Conclusion
Although some reports had already described long-term
survival in patients with metastatic melanoma treated
with chemotherapy, most of these results were observed
for patients treated with chemotherapy in association, or
with chemotherapy alone followed by surgery. In a phase
III study, 580 patients were treated with dacarbazine (Det-
icene®) alone or in association with carmustine, lomus-
tine, vincristine or an hydroxyurea. Hill et al. [2] reported
8 patients, with complete response who survived 6 years
after the treatment. Ahmann et al. [9] gave results for 15
clinical studies. Among the 503 patients, 6 presented with
complete response and long term survival of seven years
or longer. Four patients have been treated with a semus-
tine based regimen, one with a combination of vinblast-
ine, bleomycin and cisplatin, and the last one with
dianthydrogalacticol.
Petit et al. [5] described 5 out of 160 patients who went
into long-term remission 7 years after fotemustine chem-
otherapy followed by surgery. In Samuel et al. [6], 40
patients with symptomatic metastatic melanoma were
treated with procarbazine, vincristine and lomustine
(POC). Among them, two remained in complete remis-
sion at 6 and 6.5 years. Berd et al. [3] treated 147 patients
with a combination of carmustine, dacarbazine and cispl-
atin. Among the 17 complete response, 7 patients pre-
sented with long-term survival (19 to 82 months).
Coates et al. also described the case of 8 patients who
remain in long-term remission 4 to 15 years after chemo-
therapy for visceral metastatic melanoma among some
1100 patients with visceral melanoma who have received
chemotherapy, almost always with single agent dacar-
bazine or a nitrosourea treatments. For these patients, the
mechanism remains uncertain, but the author suggested
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that chemotherapeutic agents can cause mutations that
allow expression of antigenicity in tumour cells [4].
Despite these noteworthy and encouraging but also rare
results, it appears essential to increase cystemustine effi-
ciency. The main antitumor target of CENU is DNA with
generation of O6-chloroethylguanine and cross-linking
with cDNA strands [10]. The MGMT (O6-methylguanine-
DNA methyltransferase) protein removes O6-alkylgua-
nine by accepting the alkyl group on the cystein residue of
its active site. MGMT level varies considerably in normal
and tumor cells, and cells that exhibit a low MGMT level
are more sensitive to CENU [11]. Methionine restriction is
known to inhibit growth of human and animal tumor (in
vitro, and in vivo) [12]. It decreases MGMT mRNA and
activity in tumoral cells [13]. Furthermore, the potentiat-
ing effect of methionine depletion on Cystemustine treat-
ment has been shown in B16 melanoma-bearing mice
[14]. On the basis of these previous experimental results,
we have initiated a phase-I clinical trial of dietary methio-
nine restriction, in association with Cystemustine treat-
ment for adults with recurrent metastatic melanomas.
In conclusion, we described case of five out 53 patients
with metastatic melanoma, treated with Cystemustine, 60
or 90 mg/m2, and presented with complete response and
long-term disease-free survival. Despite these encouraging
results, it appears crucial to increase cystemustine effi-
ciency.
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